Report from the international union against cancer (UICC) tumor biology committee: UICC workshop on the use of dendritic cells in cancer clinical trials

Cancer

Volumn 86, Issue 12, 1999, Pages 2674-2683

  Salgaller, Michael L ^a   Thurnher, Martin ^b   Bartsch, Georg ^b   Boynton, Alton L ^a   Murphy, Gerald P ^a,c  

^a NORTHWEST HOSPITAL   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; MELANOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA;

CLINICAL TRIALS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 0033572688     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991215)86:12<2674::AID-CNCR12>3.0.CO;2-Z     Document Type: Conference Paper

References (41)

1. Lotze MT, Farhood H, Wilson CC, Storkus WJ. Dendritic cell therapy of cancer and HIV infection. In: Lotze MT, Thomson AW, editors. Dendritic cells: biology and clinical applications. San Diego: Academic Press, 1999:459-85.
2. Lotze MT, Jaffe R. Cancer. In: Lotze MT, Thomson A W, editors. Dendritic cells: biology and clinical applications. San Diego: Academic Press, 1999:325-38.
3. Amoscato AA, Prenovitz DA, Lotze MT. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 1998;161:4023-32.
4. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1-6.
5. Esche C, Shurin MR, Lotze MT. The use of dendritic cells for cancer vaccination. Mol Therapeutics 1999;1:72-81.
6. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA) specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16:364-9.
7. Wong C, Morse M, Nair SK. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother 1998;21:32-40.
8. Morse MA, Lyerly HK. Dendritic cell-based approaches to cancer immunotherapy. Exp Opin Invest Drugs 1998;7:1617-27.
9. Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol 1998; 68:122-38.
10. Knight SC, Iqball S, Roberts MS, Macatonia S, Bedford PA. Transfer of antigen between dendritic cells in the stimulation of primary T cell proliferation. Eur J Immunol 1998;28: 1636-44.
11. Murphy GP, Slack NH. Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1980;1: 375-82.
12. Tjoa B, Erickson S, Barren R III, Ragde H, Kenny G, Boynton A, et al. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995;27:63-9.
13. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-80.
14. Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998;35:144-51.
15. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997;32:272-8.
16. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
17. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999;38:73-8.
18. Gjertsen MK, Bakka A, Breivik JG, Sæterdal I, Solheim B, S¢reide O, et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995;346:1399-440.
19. Gjertsen MK, Bakka A, Breivik JG, Sæterdal I, Gedde-Dahl T II, Stokke KT, et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996;65:450-3.
20. Gjertsen MK, Bjørheim J, Sæterdal I, Myklebust J, Gaudernack G. Cytotoxic CD+ and CD8+ T lymphocytes, generated by mutant p21-ras (12 Val) peptide vaccination of a patient, recognize 12 Val dependent nested epitopes present within the vaccine peptide and kill autologous tumor cells carrying this mutation. Int J Cancer 1997;75: 784-90.
21. Höltl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M. CD83+ blood dendritic cells as a vaccine for the active, specific immunotherapy of metastatic renal cell carcinoma. Lancet 1998;352:1358.
22. Höltl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, et al. Cellular and humoral immune responses after vaccination of metastatic renal cell carcinoma patients with antigen-pulsed dendritic cells. J Urol 1999;161:777-82.
23. Timmerman JM, Davis TA, Hsu FJ, Benike C, Liles TM, Czerwinski DK, et al. Clinical trials of dendritic cell vaccination for B-cell non-Hodgkin's lymphoma. J Leukocyte Biol 1998;(Suppl 2):15.
24. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Ann Rev Med 1999;50:507-29.
25. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2: 52-8.
26. Hsu F, Caspar C, Czerwinski DD, Kwak L, Liles T, Syrengelas A, et al. Tumor-specific idiotype vaccines in the treatment of patients with B cell lymphoma: long term results of a clinical trial. Blood 1997;89:3129-35.
27. Rowly ID. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
28. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
29. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, et al. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 1987;83:445-54.
30. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82:1954-6.
31. Martin PJ, Clift RA, Fisher LD, Buckner CD, Hansen JA, Appelbaum FR, et al. HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood 1988;72: 1978-84.
32. O'Brien SG, Goldman JM. Autografting in chronic myeloid leukemia [review]. Blood Rev 1994;8:63-9.
33. The Italian Cooperative Study Group on chronic myelogenous leukemia. Interferon-alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-5.
34. BCR-ABL protein. Proc Natl Acad Sci USA 1992;89:1468.
35. BCR-ABL by human T-cells. Leukemia 1995;9:1344-8.
36. Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, et al. BCR-ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T-cells found at low frequency in the repertoire of normal donors. Blood 1996;88:2118-24.
37. Mannering SI, McKenzie JL, Fearnley DB, Hart DNJ. HLA-DR1 restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997;90:290-7.
38. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche K-O, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997;89:1133-42.
39. Smit WM, Rijnbeek M, Van Bergen CAM, De Paus R, Vervenne HAW, Van de Keur M, et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol 1997;53:216-23.
40. Nieda M, Nicol A, Kikuchi A, Kashiwase K, Taylor K, Suzuki K, et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998;91:977-83.
41. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59:56-8. [This work was published subsequent to the UICC Dendritic Cell Workshop.]